Search the Newsreel

Compugen Ltd (CGEN) - Tradingkey

This TradingKey stock analysis provides a comprehensive score for Compugen Ltd (CGEN), highlighting its healthy fundamentals, growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company has growing revenue, institutional buying, and multiple analysts rating it as a "Strong Buy" …

Earnings Preview: Compugen to Report Financial Results Pre-market on August 03

This article announces that Compugen will report its financial results pre-market on August 3. Investors are anticipating the report to assess the company's performance and future outlook.

Compugen Ltd (CGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Compugen Ltd (CGEN), detailing various financial metrics related to volatility, financial risk, and investment risk. It presents key data such as the stock's Beta, VaR, maximum drawdown, and Sharpe Ratio over different periods. The report also includes …

Compugen (CGEN) Projected to Post Earnings on Monday

Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Compugen Ltd (CGEN) stock information, focusing on its dividend and stock split history. It indicates that the company has distributed no dividends over the past five years. The page also presents current stock performance metrics and links to …

CGEN Q2'26 Earnings: revenue estimate is 1.28M USD

Compugen Ltd CGEN Cash Flow Statement

This article provides details on Compugen Ltd's (CGEN) cash flow statement, including operating, investing, and financing cash flows. It highlights the company's operating cash flow of 31.63M in fiscal 2025 and free cash flow of 31.33M in the latest quarter, along with year-over-year changes …

Compugen Ltd CGEN Balance Sheet

This article provides a detailed historical balance sheet analysis for Compugen Ltd (CGEN) on TradingKey, presenting quarterly and annual financial data. It allows users to evaluate the company's financial health by examining key metrics such as cash and short-term investments, total assets, liabilities, and …

CGEN|Compugen Ltd|Price:2.280|Chg%:-0.060

Compugen Ltd (CGEN) is currently trading at $2.28, down 2.56%. The company, which focuses on therapeutic discovery, has strong fundamentals and high growth potential, with annual revenue growth averaging 117.47% over the past three years. Despite being considered fairly valued by analysts who give …

Compugen to Participate in BTIG Biotechnology Conference 2026

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced its participation in the virtual BTIG Biotechnology Conference 2026 from July 28-29, 2026. Management will present and hold one-on-one meetings, though a replay will not be available. The company leverages its AI/ML-powered Unigen™ platform …

Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Raises Target Price to $6

Lake Street maintained its Buy rating on Compugen (CGEN.US) and increased the target price to $6. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.

Compugen to Hold 1x1 Meetings at July 28-29 BTIG Event

Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced that its management will participate in the virtual BTIG Biotechnology Conference 2026, holding 1x1 meetings with investors on July 28-29, 2026. The company will discuss its immuno-oncology pipeline, which includes clinical-stage assets like COM701, rilvegostomig …

Compugen to release Q2 2026 results, host conference call

Compugen has announced that it will release its second-quarter 2026 financial results on August 3, 2026, before the U.S. market opens. Following the release, the company will host a management conference call and webcast on the same day at 8:30 a.m. ET to discuss …

Compugen (CGEN) to Release Q2 Financial Results on August 3, 2026

Compugen Ltd (CGEN) is set to release its second-quarter financial results on August 3, 2026, before the U.S. market opens, followed by a conference call. Despite being significantly undervalued according to GuruFocus's GF Value™ and possessing strong financial health, the biopharmaceutical company faces challenges …

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

Compugen Ltd. announced it will release its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. financial markets open. Management will host a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update. Compugen …

Compugen's Cancer Immunotherapy Update Is Set for Aug. 3

Compugen (NASDAQ: CGEN; TASE: CGEN) announced it will release its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open. The company, a clinical-stage cancer immunotherapy firm utilizing an AI/ML platform, will also host a conference call and webcast at …

CGEN Q1 2026 Earnings: EPS Misses Estimates Despite Positive Stock Reaction - Return On Assets

CGEN Forecast — Price Target — Prediction for 2027

CGEN Q1 2026 Earnings: EPS Misses Estimates amid R&D Focus - Analyst Drop Coverage

Compugen Ltd. Q1 2026 Earnings Call Summary

Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN)

Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates

Compugen cancer trials, AstraZeneca and Gilead deals, cash runway into 2029

COMPUGEN ($CGEN) Releases Q1 2026 Earnings

Compugen Q1 Earnings Call Highlights

CGEN Q1'26 Earnings: revenue estimate is 1.57M USD

Compugen sets May 18 earnings release, 8:30 AM ET webcast

COMPUGEN ($CGEN) Releases Q4 2025 Earnings

Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead Of Earnings

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

What date does Compugen's (CGEN) report Earnings - Earnings Calendar & Announcement

Compugen (CGEN) Earnings Date and Reports 2026

Compugen Ltd. (CGEN) stock price, news, quote and history